查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586371

肺炎链球菌疫苗市场、规模、占有率、趋势、行业分析报告：按疫苗类型、按产品类型、按最终用户、按地区、按细分市场、预测，2024-2032 年

Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，到2032年，全球肺炎链球菌疫苗市场预计将达到144.3亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

由于人们对肺炎球菌感染的认识不断提高以及政府资助的免疫计划的扩大，肺炎球菌疫苗市场正在经历显着增长。随着公共卫生运动强调肺炎球菌疾病（包括肺炎和脑膜炎）的风险，个人和医疗保健提供者越来越多地寻求疫苗接种。此外，世界各国政府正在实施强有力的免疫举措，旨在改善社区健康并降低与肺炎球菌感染相关的医疗费用。这些计划通常包括赠款和教育资源，使服务不足的人更容易获得疫苗。随着意识的不断提高和疫苗接种工作的加强，对肺炎球菌疫苗的需求预计将大幅增加，对肺炎球菌疫苗市场的成长产生积极影响。

肺炎链球菌疫苗市场是由促进广泛接种疫苗的政府措施和卫生政策所推动的。这些计划旨在透过减少肺炎和脑膜炎等肺炎球菌疾病的发生率来改善公共卫生。随着各国政府实施全面的免疫策略，包括资金和宣传活动，获得疫苗的机会将会改善，进而提高疫苗接种率。

生物技术和市场参与者之间不断发展的合作伙伴关係旨在开发更有效的肺炎球菌结合疫苗 (PCV)，这将推动未来几年肺炎球菌疫苗市场的成长。例如，2023年6月，SK Bioscience与Sanofi合作开发了GBP410，这是一种21价PCV，在婴儿和婴幼儿的2期试验中显示出正面结果。同样，2024 年 3 月，Pfizer的 20 价 PCV PREVENAR 20 获得欧盟委员会批准，用于欧洲和世界各地的婴儿、儿童和青少年疫苗接种。此类策略联盟将加强研究能力、加速市场准入并扩大疫苗准入范围，最终推动预计的多年市场成长。

肺炎链球菌疫苗市场报告亮点

肺炎链球菌多醣体疫苗 (PPV) 细分市场在 2023 年占据最大的市场占有率，这主要是由于其全球接受度高且易于取得。

肺炎链球菌结合疫苗 (PCV) 领域预计将在研究期间出现最高成长，因为 PCV 涵盖肺炎链球菌范围更广。

Prevnar 13因其适合广泛的年龄层和更有效的治疗而在2023年占据最大的市场占有率。

由于对肺炎球菌疫苗开发的投资增加，预计亚太地区将在研究期间实现最快的成长。

全球公司包括GSK plc、Pfizer Inc、Merck、Serum Institute、CSL Ltd.、Sanofi。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球肺炎链球菌疫苗市场洞察

  • 市场快照
  • 肺炎链球菌疫苗市场动态
    • 促进因素和机会
      • 所有年龄层的肺炎球菌感染发生率不断上升推动市场成长
      • 促进广泛疫苗接种的卫生政策正在推动市场规模扩大
    • 抑制因素和课题
      • 监理障碍
  • PESTEL 分析
  • 肺炎链球菌疫苗市场趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第五章全球肺炎链球菌疫苗市场：依疫苗类型划分

  • 主要发现
  • 简介
  • 肺炎链球菌结合疫苗
  • 肺炎链球菌多醣体疫苗

第 6 章全球肺炎链球菌疫苗市场：依产品

  • 主要发现
  • 简介
  • Prevenar 13
  • Synflorix
  • Pneumovax 23
  • 其他产品

第 7 章全球肺炎链球菌疫苗市场：依最终使用者划分

  • 主要发现
  • 简介
  • 公共部门
  • 私部门

第 8 章全球肺炎链球菌疫苗市场：按地区

  • 主要发现
  • 简介
    • 肺炎链球菌疫苗市场评估：地区，2019-2032
  • 北美
    • 北美：依疫苗类型划分，2019-2032 年
    • 北美：依产品分类，2019-2032 年
    • 北美：依最终使用者划分，2019-2032 年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依疫苗类型划分，2019-2032 年
    • 欧洲：依产品分类，2019-2032 年
    • 欧洲：依最终使用者划分，2019-2032 年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 欧洲其他地区
  • 亚太地区
    • 亚太地区：依疫苗类型划分，2019-2032 年
    • 亚太地区：依产品分类，2019-2032 年
    • 亚太地区：依最终使用者划分，2019-2032 年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳大利亚
    • 亚太地区其他地区
  • 中东/非洲
    • 中东和非洲：依疫苗类型划分，2019-2032 年
    • 中东与非洲：依产品分类，2019-2032 年
    • 中东和非洲：按最终用户划分，2019-2032 年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东/非洲
  • 拉丁美洲
    • 拉丁美洲：依疫苗类型划分，2019-2032 年
    • 拉丁美洲：依产品分类，2019-2032 年
    • 拉丁美洲：依最终使用者划分，2019-2032 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协定/揭露

第十章公司简介

  • GSK plc
  • Pfizer Inc.
  • Merck KGaA
  • Serum Institute of India Pvt. Ltd.
  • CSL Ltd.
  • Sanofi S.A
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd
  • Johnson & Johnson
  • AstraZeneca
  • Novavax
Product Code: PM5107

The global pneumococcal vaccine market size is expected to reach USD 14.43 billion by 2032, according to a new study by Polaris Market Research. The report "Pneumococcal Vaccine Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pneumococcal vaccine market is experiencing significant growth driven by increased awareness about pneumococcal infections and the expansion of government-sponsored immunization programs. As public health campaigns highlight the dangers of pneumococcal disease, including pneumonia and meningitis, individuals and healthcare providers are more inclined to seek vaccination. Additionally, governments worldwide are implementing robust immunization initiatives aimed at enhancing community health and reducing healthcare costs associated with pneumococcal diseases. These programs often include subsidies and educational resources, making vaccines more accessible to underserved populations. As awareness continues to rise and vaccination efforts intensify, the demand for pneumococcal vaccines is expected to increase substantially, impacting the pneumococcal vaccine market growth positively.

The pneumococcal vaccine market is driven by government initiatives and health policies that promote widespread vaccination. These programs aim to enhance public health by reducing the incidence of pneumococcal diseases, such as pneumonia and meningitis. As governments implement comprehensive immunization strategies, including funding and awareness campaigns, accessibility to vaccines improves, leading to higher vaccination rates.

Increasing partnerships between biotech firms and market players aimed at developing more effective pneumococcal conjugate vaccines (PCVs) are fueling the pneumococcal vaccine market growth in forecast years. For Instance, in June 2023, SK Bioscience collaborated with Sanofi to create GBP410, a 21-valent PCV that demonstrated positive results in Phase 2 studies involving toddlers and infants. Similarly, in March 2024, Pfizer's PREVENAR 20, a 20-valent PCV, received approval from the European Commission to immunize infants, children, and adolescents across Europe and globally. These strategic alliances enhance research capabilities, expedite development timelines, and expand vaccine access, ultimately driving market growth during projected years.

Pneumococcal Vaccine Market Report Highlights

The pneumococcal polysaccharide vaccine (PPV) segment accounted for the largest market share in 2023 primarily due to global acceptance and easy availability.

The Pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, as PCV covers more range of the streptococcus pneumoniae.

The Prevnar 13 segment accounted for the largest market share in 2023, as it caters to a wider range of age, and is more efficient in treating the disease.

The Asia Pacific is projected to register the fastest growth over the study period, attributable to the increasing investment in pneumococcal vaccine development.

The global players are GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd., and Sanofi.

Polaris Market Research has segmented the pneumococcal vaccine market report based on vaccine type, product type, distribution channel, and region:

By Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Pneumococcal conjugate vaccine (PCV)
  • Pneumococcal polysaccharide vaccine (PPV)

By Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Prevnar 13
  • Synflorix
  • Pneumovax23

By Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Distribution partner companies
  • Non-governmental Organizations
  • Government Authorities

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Vaccine Types
    • 3.2.1. Primary Vaccine Types
    • 3.2.2. Secondary Vaccine Types

4. Global Pneumococcal Vaccine Market Insights

  • 4.1. Pneumococcal Vaccine Market - Market Snapshot
  • 4.2. Pneumococcal Vaccine Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Pneumococcal Disease Across All Age Groups is Driving Market Growth
      • 4.2.1.2. Health Policies Promoting Widespread Vaccination is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Regulatory Hurdles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pneumococcal Vaccine Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pneumococcal Vaccine Market, by Vaccine Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • 5.3. Pneumococcal conjugate vaccine
    • 5.3.1. Global Pneumococcal Vaccine Market, by Pneumococcal conjugate vaccine, by Region, 2019-2032 (USD billion)
  • 5.4. Pneumococcal polysaccharide vaccine
    • 5.4.1. Global Pneumococcal Vaccine Market, by Pneumococcal polysaccharide vaccine, by Region, 2019-2032 (USD billion)

6. Global Pneumococcal Vaccine Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • 6.3. Prevnar 13
    • 6.3.1. Global Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2019-2032 (USD billion)
  • 6.4. Synflorix
    • 6.4.1. Global Pneumococcal Vaccine Market, by Synflorix, by Region, 2019-2032 (USD billion)
  • 6.5. Pneumovax23
    • 6.5.1. Global Pneumococcal Vaccine Market, by Pneumovax23, by Region, 2019-2032 (USD billion)
  • 6.6. Other Product
    • 6.6.1. Global Pneumococcal Vaccine Market, by Other Product, by Region, 2019-2032 (USD billion)

7. Global Pneumococcal Vaccine Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 7.3. Public Sector
    • 7.3.1. Global Pneumococcal Vaccine Market, by Public Sector, by Region, 2019-2032 (USD billion)
  • 7.4. Private Sector
    • 7.4.1. Global Pneumococcal Vaccine Market, by Private Sector, by Region, 2019-2032 (USD billion)

8. Global Pneumococcal Vaccine Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • 8.3. Pneumococcal Vaccine Market - North America
    • 8.3.1. North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.3.2. North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.3.3. North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.4. Pneumococcal Vaccine Market - U.S.
      • 8.3.4.1. U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.4.2. U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.4.3. U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.5. Pneumococcal Vaccine Market - Canada
      • 8.3.5.1. Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.5.2. Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.5.3. Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.4. Pneumococcal Vaccine Market - Europe
    • 8.4.1. Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.4.2. Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.4.3. Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.4. Pneumococcal Vaccine Market - UK
      • 8.4.4.1. UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.4.2. UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.4.3. UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.5. Pneumococcal Vaccine Market - France
      • 8.4.5.1. France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.5.2. France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.5.3. France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.6. Pneumococcal Vaccine Market - Germany
      • 8.4.6.1. Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.6.2. Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.6.3. Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.7. Pneumococcal Vaccine Market - Italy
      • 8.4.7.1. Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.7.2. Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.7.3. Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.8. Pneumococcal Vaccine Market - Spain
      • 8.4.8.1. Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.8.2. Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.8.3. Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.9. Pneumococcal Vaccine Market - Netherlands
      • 8.4.9.1. Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.9.2. Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.9.3. Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.10. Pneumococcal Vaccine Market - Russia
      • 8.4.10.1. Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.10.2. Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.10.3. Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.11. Pneumococcal Vaccine Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.11.2. Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.11.3. Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.5. Pneumococcal Vaccine Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.5.2. Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.5.3. Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.4. Pneumococcal Vaccine Market - China
      • 8.5.4.1. China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.4.2. China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.4.3. China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.5. Pneumococcal Vaccine Market - India
      • 8.5.5.1. India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.5.2. India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.5.3. India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.6. Pneumococcal Vaccine Market - Malaysia
      • 8.5.6.1. Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.6.2. Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.6.3. Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.7. Pneumococcal Vaccine Market - Japan
      • 8.5.7.1. Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.7.2. Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.7.3. Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.8. Pneumococcal Vaccine Market - Indonesia
      • 8.5.8.1. Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.8.2. Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.8.3. Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.9. Pneumococcal Vaccine Market - South Korea
      • 8.5.9.1. South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.9.2. South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.9.3. South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.10. Pneumococcal Vaccine Market - Australia
      • 8.5.10.1. Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.10.2. Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.10.3. Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.11. Pneumococcal Vaccine Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.6. Pneumococcal Vaccine Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.6.2. Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.6.3. Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.4. Pneumococcal Vaccine Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.4.2. Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.4.3. Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.5. Pneumococcal Vaccine Market - UAE
      • 8.6.5.1. UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.5.2. UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.5.3. UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.6. Pneumococcal Vaccine Market - Israel
      • 8.6.6.1. Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.6.2. Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.6.3. Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.7. Pneumococcal Vaccine Market - South Africa
      • 8.6.7.1. South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.7.2. South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.7.3. South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.8. Pneumococcal Vaccine Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.7. Pneumococcal Vaccine Market - Latin America
    • 8.7.1. Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.7.2. Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.7.3. Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.4. Pneumococcal Vaccine Market - Mexico
      • 8.7.4.1. Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.4.2. Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.4.3. Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.5. Pneumococcal Vaccine Market - Brazil
      • 8.7.5.1. Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.5.2. Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.5.3. Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.6. Pneumococcal Vaccine Market - Argentina
      • 8.7.6.1. Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.6.2. Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.6.3. Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.7. Pneumococcal Vaccine Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.7.2. Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.7.3. Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. GSK plc
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Merck KGaA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Serum Institute of India Pvt. Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. CSL Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi S.A
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Walvax Biotechnology Co., Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Beijing Minhai Biotechnology Co., Ltd
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson & Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. AstraZeneca
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Novavax
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development

List of Tables:

  • Table 1 Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 2 Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 3 Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 4 North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 5 North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 6 North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 7 U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 8 U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 9 U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 10 Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 11 Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 12 Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 13 Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 14 Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 15 Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 16 UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 17 UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 18 UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 19 France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 20 France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 21 France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 22 Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 23 Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 24 Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 25 Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 26 Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 27 Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 28 Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 29 Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 30 Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 31 Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 32 Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 33 Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 34 Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 35 Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 36 Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 37 Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 38 Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 39 Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 40 Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 41 Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 42 Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 43 China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 44 China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 45 China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 46 India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 47 India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 48 India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 49 Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 50 Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 51 Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 52 Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 53 Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 54 Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 55 Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 56 Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 57 Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 58 South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 59 South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 60 South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 61 Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 62 Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 63 Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 64 Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 65 Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 66 Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 67 Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 68 Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 69 Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 70 Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 71 Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 72 Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 73 UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 74 UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 75 UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 76 Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 77 Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 78 Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 79 South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 80 South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 81 South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 82 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 83 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 84 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 85 Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 86 Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 87 Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 88 Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 89 Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 90 Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 91 Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 92 Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 93 Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 94 Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 95 Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 96 Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 97 Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 98 Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 99 Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

List of Figures:

  • Figure 1. Global Pneumococcal Vaccine Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Vaccine Type
  • Figure 7. Global Pneumococcal Vaccine Market, by Vaccine Type, 2023 & 2032 (USD billion)
  • Figure 8. Market by Product
  • Figure 9. Global Pneumococcal Vaccine Market, by Product, 2023 & 2032 (USD billion)
  • Figure 10. Market by End User
  • Figure 11. Global Pneumococcal Vaccine Market, by End User, 2023 & 2032 (USD billion)
  • Figure 12. Global Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • Figure 13. Strategic Analysis - Global Pneumococcal Vaccine Market